EGFR and non-small cell lung carcinoma: For patients with metastatic NSCLC whose tumors express PD‐L1 (TPS ≥ 1%), with disease progression on or after platinum‐containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA‐approved therapy for these aberrations prior to receiving pembrolizumab [19]